Skip to main content
. 2024 Apr 23;13:45. doi: 10.1186/s40164-024-00507-5

Table 3.

The agent-specific reported adverse effects associated with HDACis

HDACi Specific adverse effects reported in clinical trials
Panobinostat Cardiac ischaemia, haemorrhage
Vorinostat Hyper-glycaemia, pulmonary embolism, deep vein thrombosis
Belinostat Infections, tumour lysis syndrome
Romidepsin Infections, tumour lysis syndrome
Chidamide Raised creatine phosphokinase levels, pericardial effusion